All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2017-04-13T14:43:52.000Z

AACR 2017 | Poster 4672/3 – Novel epigenetic approach to relapsed Mantle Cell Lymphoma based on dual inhibition of EZH1/EZH2

Apr 13, 2017
Share:

Bookmark this article

At the American Association for Cancer Research (AACR) annual meeting in Washington, DC, USA, on Tuesday 4th April, a poster session titled “Epigenetics and DNA Repair” took place.

One of the posters on display (4672 / 3) was titled “Novel epigenetic approach to relapsed mantle cell lymphoma based on dual inhibition of EZH1/EZH2” by Shuhei Fujita from the National Cancer Center Research Institute, Tokyo, Japan, and colleagues.

The group used OR-S1, a novel dual inhibitor of EZH1/2, to demonstrate that EZH1/2 inhibition is an encouraging therapeutic strategy for MCL. In addition to in vitro assays using MCL cell lines, they orally administered OR-S1 to a xenograft (PDX) murine model, using cells from a heavily pretreated and relapsed MCL patient.

Key Highlights:

  • In vitro assays using MCL cell lines demonstrated that OR-S1 inhibited cell growth; the effect was much greater than administration of the single EZH2 inhibitor (GSK126)
  • IC50 of OR-S1 was about one tenth of GSK126
  • In further analyses of MCL cell lines, those exposed to OR-S1 underwent cell cycle arrest (at G1)
  • A dose-dependent reduction in phosphorylated Retinoblastoma protein and cell differentiation was observed
  • Administration of OR-S1 increased cell surface expression of hCD138
  • RNA-seq analysis of MCL cell lines indicated that cell cycle-related signaling was significantly affected and that CDKN1C (TP57) was one of the genes most markedly upregulated by OR-S1
  • ChIP qPCR of MCL cell lines demonstrated that the CDKN1C locus was strongly marked by H3K27 tri-methylation; OR-S1 induced a significant reduction in the level of this histone marker
  • OR-S1 strongly inhibited proliferation of patient-derived tumors; no serious side effects reported
  • Administration of OR-S1 alone to PDX mice induced increased expression of CDKN1C

In summary, dual inhibition of EZH1/2 increases CDKN1C expression, resulting in cell cycle arrest and inhibition of cell growth in MCL. The poster was concluded by stating that the data presented indicates that dual inhibition of EZH1/2 is a potential therapeutic strategy for patients with MCL.

  1. Fujita S. et al. Novel epigenetic approach to relapsed mantle cell lymphoma based on dual inhibition of EZH1/EZH2 [Poster]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; 2017. Poster nr [4672 / 3].

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox